Pancreatic Cancer Research

ResearcherHeidelberg UniversityNo recent work listed

Lars Grenacher

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0508-0778; OpenAlex author ID A5057203985. Sources: OpenAlex.

Their work

Papers
17 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
0
Collaborators
42
Papers, trials and grants by year

2011: 2 papers · 2012: 2 papers · 2013: 2 papers · 2014: none · 2015: 2 papers · 2016: 3 papers · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: none · 2021: 2 papers · 2022: none · 2023: 2 papers

Papers 17

  1. [Autoimmune pancreatitis versus pancreatic cancer]. Co-author DOI 10.1007/s00117-023-01240-6↗
  2. Evaluation and timing optimization of CT perfusion first pass analysis in comparison to maximum slope model in pancreatic adenocarcinoma. Co-author DOI 10.1038/s41598-023-37381-w↗
  3. Computed Tomography Perfusion Analysis of Pancreatic Adenocarcinoma using Deconvolution, Maximum Slope, and Patlak Methods - Evaluation of Diagnostic Accuracy … Last author DOI 10.1055/a-1401-0333↗
  4. Assessment of tissue perfusion of pancreatic cancer as potential imaging biomarker by means of Intravoxel incoherent motion MRI and CT perfusion: correlation w… Co-author DOI 10.1186/s40644-021-00382-x↗
  5. A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients w… Co-author DOI 10.1080/2162402x.2017.1303584↗
  6. [Criteria for resectability of pancreatic cancer and postoperative imaging]. Co-author DOI 10.1007/s00117-017-0326-8↗
  7. IVIM DW-MRI of autoimmune pancreatitis: therapy monitoring and differentiation from pancreatic cancer. Co-author DOI 10.1007/s00330-015-4041-4↗
  8. Dual-Energy Perfusion-CT in Recurrent Pancreatic Cancer - Preliminary Results. Co-author DOI 10.1055/s-0042-105765↗
  9. Synthesis and functionalization of protease-activated nanoparticles with tissue plasminogen activator peptides as targeting moiety and diagnostic tool for panc… Co-author DOI 10.1186/s12951-016-0236-3↗
  10. Targeted diagnostic magnetic nanoparticles for medical imaging of pancreatic cancer. Co-author DOI 10.1016/j.jconrel.2015.07.017↗
  11. Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlle… Co-author DOI 10.1080/2162402x.2014.1001217↗
  12. Dual-energy perfusion-CT of pancreatic adenocarcinoma. Last author DOI 10.1016/j.ejrad.2012.09.012↗
  13. Re-resection for isolated local recurrence of pancreatic cancer is feasible, safe, and associated with encouraging survival. Co-author DOI 10.1245/s10434-012-2762-z↗
  14. Cachexia but not obesity worsens the postoperative outcome after pancreatoduodenectomy in pancreatic cancer. Co-author DOI 10.1016/j.surg.2012.05.028↗
  15. Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients… Co-author DOI 10.1186/1471-2407-12-361↗
  16. Enhancing pancreatic adenocarcinoma delineation in diffusion derived intravoxel incoherent motion f-maps through automatic vessel and duct segmentation. Co-author DOI 10.1002/mrm.22931↗
  17. Anaplastic pancreatic cancer: Presentation, surgical management, and outcome. Co-author DOI 10.1016/j.surg.2010.04.026↗

Closest collaborators

The 25 strongest of 42 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Miriam Klauß · 7 shared papers, 2011–2023 · strength 0.66
  2. Wolfram Stiller · 5 shared papers, 2013–2023 · strength 0.56
  3. Stephan Skornitzke · 4 shared papers, 2016–2023 · strength 0.52
  4. Philipp Mayer · 3 shared papers, 2021–2023 · strength 0.46
  5. Markus Sebastian Juchems · 2 shared papers, 2017–2023 · strength 0.41
  6. Franziska L. Fritz · 4 shared papers, 2013–2021 · strength 0.37
  7. Thilo Hackert · 5 shared papers, 2011–2021 · strength 0.28
  8. Johannes Weßling · 1 shared paper, 2023 · strength 0.26
  9. Andreas Georg Schreyer · 1 shared paper, 2023 · strength 0.26
  10. Marco Koell · 2 shared papers, 2021 · strength 0.26
  11. Neha Vats · 1 shared paper, 2023 · strength 0.19
  12. Jens Werner · 5 shared papers, 2012–2016 · strength 0.19
  13. Klaus Hermann Maier-Hein · 2 shared papers, 2016–2021 · strength 0.19
  14. Markus Wolfgang Büchler · 5 shared papers, 2011–2018 · strength 0.18
  15. Matthias M. Gaida · 2 shared papers, 2011–2021 · strength 0.14
  16. Friedrich Hubertus Schmitz-Winnenthal · 3 shared papers, 2012–2018 · strength 0.12
  17. Nicolas Hohmann · 3 shared papers, 2012–2018 · strength 0.12
  18. Philipp Beckhove · 3 shared papers, 2012–2018 · strength 0.12
  19. Thomas Schmidt · 2 shared papers, 2015–2018 · strength 0.10
  20. Christoph Springfeld · 2 shared papers, 2015–2018 · strength 0.10
  21. Bram Stieltjes · 2 shared papers, 2011–2016 · strength 0.09
  22. Werner Hartwig · 3 shared papers, 2011–2013 · strength 0.09
  23. Sophie Dobiasch · 2 shared papers, 2015–2016 · strength 0.09
  24. Klaus Felix · 2 shared papers, 2015–2016 · strength 0.09
  25. Liron Limor Israel · 2 shared papers, 2015–2016 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.